Traws Pharma Secures PIPE Financing for Influenza Trial

Traws Pharma ( (TRAW) ) has issued an announcement.

On April 15, 2026, Traws Pharma announced that it had priced a private investment in public equity (PIPE) offering of approximately $10 million in common stock and pre-funded warrants, alongside Series A, B and C warrants that could deliver up to an additional $50 million if fully exercised. The financing, led by Sirenia Capital Management and completed on April 15, 2026 with funding expected on April 16, 2026, was priced at-the-market under Nasdaq rules and is intended to fund a Phase 2a human challenge trial of influenza candidate tivoxavir marboxil in the United Kingdom.

The structure ties most of the potential $50 million follow-on capital to clinical, regulatory and shareholder milestones, including U.K. regulator approval to run the challenge trial, positive data readouts and shareholder authorization for warrant exercises, aligning future funding with program progress but also concentrating execution risk. Traws entered into a registration rights agreement to register the resale of the shares and warrant shares, and accepted issuance and registration restrictions for a limited period, underscoring the company’s reliance on this non-dilutive-at-signing but potentially highly dilutive financing to advance its lead influenza program and support its longer-term positioning in the competitive antiviral market.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.

The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule antiviral therapies targeting major respiratory viral threats, including seasonal influenza, H5N1 bird flu and COVID-19/Long COVID. Its lead candidates include tivoxavir marboxil, in development as a once-monthly prophylactic and potential single-dose treatment for influenza, and ratutrelvir, a ritonavir-independent COVID-19 therapy targeting the viral main protease.

The company also continues to seek development and commercialization partners for its legacy oncology assets, rigosertib and narazaciclib, as it refocuses its portfolio on antiviral programs addressing resistant or hard-to-treat virus strains. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to advance its programs toward real-world clinical use in high-need infectious disease settings.

Average Trading Volume: 146,213

Technical Sentiment Signal: Strong Sell

Current Market Cap: $12.87M

For an in-depth examination of TRAW stock, go to TipRanks’ Overview page.